VCFG publications and other resources

Key publications

Choo N, Ramm S, Luu J, Winter JM, Selth LA, Dwyer AR, Frydenberg M, Grummet J, Sandhu S, Hickey TW, Tilley WD, Taylor RA, Risbridger GP, Lawrence MG and Simpson KJ. High-throughput imaging assay for drug screening of 3D prostate cancer organoids. 2021 SLAS Discovery

Carthew J, Abdelmaksoud HH, Cowley KJ, Hodgson-Garms M, Elnathan R, Spatz JP, Brugger J, Thissen H, Simpson KJ, Voelcker NH, Frith JE and Cadarso VJ. Towards more relevant microenvironments in biological screening platforms by micro and nanotopographic patterning of standard cell cultureware. 2021 Advanced Functional Materials 

Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow J, Fan Z, Blyth B, McLeod V, Visser J HA, Pavic K, Martin B P,  Gregory G, Demosthenous E, Zehoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly M, Newbold A, Simpson KJ, Kauko O, Harvey K, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. A PP2A-Integrator complex fine-tunes transcription by opposing CDK9. 2021 Cell Jun 10:184(12):3143-3162.e32 

Lawrence MG, Porter LH, Choo N, Pook D, Grummet J, Pezaro CJ, Sandhu S, Ramm S, Luu J, Bakshi A, Goode DL, Sanij E, Pearson RB, Hannan RD, Simpson KJ, Taylor RA, Risbridger GA, Furic L. CX-5641 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition. 2021 Molecular Cancer Therapeutics 

Duivenvoorden HM, Brockwell NK, Nowell CJ, Simpson KJ* and Parker BS*.  High-throughput siRNA 3D co-cultures to identify myoepithelial cell-derived breast cancer suppressor proteins. Sci DATA 2021, May 28; 8(1):147 

Behrenbruch C, Foroutan M, Lind P, Smith J, Cooper B, Shembrey C, Grandin M, Ramm S, Cowley K, Nikolic I, Luu J, Cursons J, Millen R, Patch A, Huntington N, Michael M,  Knowles B, Thomson BNJ, Puisieux A,  Ramsay RG, Grimmond SM, Simpson KJ, Heriot AG and Hollande F. Targeting of TP53-independent cell cycle checkpoints overcomes FOLFOX resistance in Metastatic Colorectal Cancer. 2021 BioRxiv 

Xu JJ, Chalk AM, Nikolic I, Simpson KJ, Smeets MF, Walkley CR. Genome-wide CRISPR screen identifies cell cycle as a synthetic lethal pathway with SRSF2P95H mutation. 2021 Blood Advances 

Ong SY, Schuelein R, Thomas DW, Handoko Y, Freytag S, Bahlo M, Simpson KJ and Hartland EL. Genome-wide RNAi screen identifies host ubiquitination as important for L. pneumophila Dot/Icm effector translocation. 2021 Cellular Microbiology 

Ceder S, Eriksson SE, Cheteh EH, Dawar S, Corrales Benitez M, Bykov VJN, Fujihara KM, Grandin M, Li X, Ramm S, Behrenbruch C, Simpson KJ, Hollande F, Abrahmsen L, Clemons NJ, Wiman KG. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Mol Med. 2021 Feb 5;13(2):e10852. 

Fujihara KM, Zhang B, Jackson TD, Nijiagel B, Ang CS, Nikolic I, Sutton V, Trapani J, Simpson KJ, Stojanovski D, Leimuehler S, Haupt S, Phillips WA, Clemons NJ. Genome-wide CRISPR screens reveal APR-246 (Eprenetapopt) triggers ferroptosis and inhibits iron-sulfur cluster biogenesis. 2020 BioRxiv 

Fujihara KM, Corrales-Benitez M, Cabalag CS, Zhang BZ, Ko HS, Liu DS, Simpson KJ, Haupt Y, Haupt S, Phillips WA, Clemons NJ. SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation status. 2020 BioRxiv

King LE, Xhang HH, Could CM, Thomas DW, Whitehead LW, Simpson KJ, Burgess AW, Faux MC. Genes regulating membrane-associated E-cadherin and proliferation in adenomatous polyposis coli mutant colon cancer cells: High content RNAi screen. PLoS One 2020 

Smith LK, Parmenter T, Gould CM, Madhamshettiwar PB, Sheppard KE, Simpson KJ* and McArthur GA.* Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAFv600 melanoma cells. Sci Data 2020 

Bortnik V, Montalvo, A, Yu M, Julcher B, Nikolic I, Simpson KJ, McMillen NJ, Idris A. Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells. Journal of Microbiology, Immunology and Infection. 2020 

Gotovac JR, Liu DS, Yates MJ, Milne JV, Macpherson AA, Simpson KJ, Eslick GD, Mitchell C, Duong CP, Phillips WA and Clemons NJ. GRB7 amplification is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma. Journal of Pathology 2020 

Cipponi A, Goode DL, Bedo J, McCabe MJ, Pajic M, Croucher DR, Rajal AG, Junankar SR, Saunders DN, Lobachevsky P, Papenfuss AT, Nessem D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, Long GV, Blay JY, Thomas DM. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. 2020 Science 

Sharp MF, Murphy VJ, Van Twest S, Tan W, Luu J, Simpson KJ, Deans AJ, Crismani W. Methodology for the Identification of Small Molecule Inhibitors of the Fanconi Anaemia Ubiquitin E3 Ligase Complex. Sci Rep. 2020 

Newton P, Thomas DR, Reed SCO, Lau N, Xu B, Ong SY, Pasricha S, Madhamshettiwar PB, Edgington-Mitchell LE, Simpson KJ, Roy CR, Newton HJ. Lysosomal degradation products induce Coxiella burnetii virulence. Proc Natl Acad Sci USA, 2020 

Bhatia S, Blick T, Pinto C, Waltham M, Monkman J, Ivanova E, Pollock PM, Nagaraj SH, Wiegmans AP, Haviv I, Simpson KJ, Thompson EW.  Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen. Cancers (Basel) 2020 

Chew NJ, Nguyen EV, Su S-P, Novy K, Luu J, Chan HC, Nguyen LK, Simpson KJ, Lee RS and Daly RJ. FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal. 2020

Turner RE, Henneken LM, Liem-Weits M, Harrison PF, Swaminathan A, Vary R, Nikolic I, Simpson KJ, Powell DR, Beilharz T and Dichtl B. Requirement for Cleavage Factor IIm in the Control of Alternative Polyadenylation in Breast Cancer Cells. RNA 2020 

Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PBSimpson KJ, Ellis S, Kang J, Cullinane C, Sheppard KE, Hannan KM, Hannan RD, Sanij E, Pearson RB, Chan KT. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. Br J Cancer. 2020 

Other resources

Office of the Gene Technology Regulator

Australasian Genomic Technologies Association (AGTA)

Australian Cancer Research Foundation

Australian Phenomics Network (APN)

APN at the Harry Perkins Institute of Medical Research

Australian Government Education Investment Fund

The Jack Brockhoff Foundation

Society for Biomolecular Imaging and Informatics: first conference September 2014

RNAi Global Initiative: resources and information about RNAi

Thermo Scientific: Dharmacon RNAi reagent information

Victorian Department of Economic Development, Jobs, Transport and Resources

Victorian Platform Technologies Network (VPTN)

related experts

A/Prof Kaylene Simpson